anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Suvorexant
Trial phase: Phase 2
ATC code: N05CJ01 | N05CM19
SMILES: [H][C@@]1(C)CCN(c2nc3cc(Cl)ccc3o2)CCN1C(=O)c1cc(C)ccc1-n1nccn1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Subjects will receive suvorexant (10 mg week 1, 20 mg week 2), once daily at 10 PM.

suvorexant: Subjects will receive suvorexant capsules (10 mg week 1, 20 mg week 2), once daily at 10 PM.
Eligibility criteria:
Inclusion Criteria:

meet current DSM-5 criteria for cocaine use disorder (CUD) of at least moderate severity (≥4 symptoms)

Exclusion Criteria:

current DSM-IV diagnosis of any psychoactive substance dependence other than cocaine, marijuana, or nicotine
have a DSM-IV axis I psychiatric disorder or neurological disease or disorder requiring ongoing treatment and/or making study participation unsafe
significant current suicidal or homicidal ideation
medical conditions contraindicating administration of suvorexant (e.g., severe pulmonary disease, severe cardiovascular disease or clinically abnormal EEG, severe liver or kidney disease, seizure disorder, or sleep disorder - particularly narcolepsy)
taking medications known to have significant drug interactions with the study medication(s) (e.g., MAO inhibitors, anticonvulsants, haloperidol, phenothiazines, anesthetics, and all sedatives)
currently or recently (last 3 months) treated for substance use [other than cocaine or nicotine] or another psychiatric condition
conditions of probation or parole requiring reports of drug use to officers of the court; (8) impending incarceration
pregnant or nursing for female patients
inability to read, write, or speak English [required for lab tasks and psychometric scales]
unwillingness to sign a written informed consent form
subjects with alcohol use disorders or are drinking > 7 alcoholic drinks per week. All subjects who are excluded will be given referral information to other local treatment programs.
Intervention: Ropivacaine
Trial phase: Phase 4
ATC code: N01BB09
SMILES: CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 27
Group description: Subject will receive a mid-thigh adductor block method using ropivacaine (0.5%, 15 mL).

Ropivacaine: Ropivacaine is routinely used to perform localized blockade prior to surgery to improve management of postoperative pain.
Eligibility criteria:
Inclusion Criteria:

Adults aged 18 years or older
Individuals undergoing surgery of the medial foot, medial ankle, or medial leg for which the anesthetic plan includes an adductor canal nerve block

Exclusion Criteria:

Any known deficit of the ipsilateral lumbar nerve roots, ipsilateral lumbar plexus, ipsilateral femoral nerve, obturator nerve or saphenous nerve including diabetic peripheral neuropathy
Any local disorder of the skin or otherwise where blockade is to be performed
Body mass index >50
American Society of Anesthesiologists (ASA) classification greater than 3
Allergy to amide local anesthetic medications
Pregnancy
Incarceration
Inability to understand study procedures including inability to understand the English language
Intervention: Ropivacaine
Trial phase: Phase 4
ATC code: N01BB09
SMILES: CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 25
Group description: Subject will receive a distal-thigh adductor block method using ropivacaine (0.5%, 15 mL).

Ropivacaine: Ropivacaine is routinely used to perform localized blockade prior to surgery to improve management of postoperative pain.
Eligibility criteria:
Inclusion Criteria:

Adults aged 18 years or older
Individuals undergoing surgery of the medial foot, medial ankle, or medial leg for which the anesthetic plan includes an adductor canal nerve block

Exclusion Criteria:

Any known deficit of the ipsilateral lumbar nerve roots, ipsilateral lumbar plexus, ipsilateral femoral nerve, obturator nerve or saphenous nerve including diabetic peripheral neuropathy
Any local disorder of the skin or otherwise where blockade is to be performed
Body mass index >50
American Society of Anesthesiologists (ASA) classification greater than 3
Allergy to amide local anesthetic medications
Pregnancy
Incarceration
Inability to understand study procedures including inability to understand the English language
Intervention: Atomoxetine
Trial phase: Phase 2
ATC code: N06BA09
SMILES: CNCC[C@@H](Oc1ccccc1C)c1ccccc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 12
Group description: 40 mg atomoxetine paired with task-oriented therapy for 10 consecutive weekdays

Atomoxetine: Subjects will receive a single daily oral dose of 40 mg of atomoxetine. We will administer 2 hours/daily of motor training sixty minutes after drug intake.
Eligibility criteria:
Inclusion Criteria:

Chronic stroke patients
Single stroke
Chronic (more than 6 months after from stroke)
At least 21 years old, but there is no upper age range for this project.
Participants NOT able to extend the affected metacarpophalangeal joints at least 10° and the wrist 20°.

Exclusion Criteria:

History of head injury with loss of consciousness
History of severe alcohol or drug abuse
History of psychiatric illness
Unstable cardiac dysrhythmia
High blood pressure (systolic pressure >160 mm Hg and/or diastolic pressure >100 mm Hg)
History of myocardial infarction or unstable angina
Pregnancy
Glaucoma, history of hypersensitivity or idiosyncrasy to sympathomimetic drugs.
Subjects using drugs suspected of interfering with plasticity, such as MAOI, alpha-adrenergic antagonists, benzodiazepines, muscarinic receptor antagonists, dopaminergic antagonists, or other neuroleptics within 3 months of recruitment.
Intervention: Alvimopan
Trial phase: Phase 4
ATC code: A06AH02
SMILES: C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(=O)O)CC[C@@]1(C)c1cccc(O)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 49
Group description: 12 mg alvimopan twice a day (either by mouth or by (NG) nasogastric tube) for up to seven days post-operatively, or until the time of discharge, whichever occurs first, to a maximum of 15 doses.

Alvimopan: Alviimopan 12 mg twice daily up to 15 doses
Eligibility criteria:
Inclusion Criteria:

Major spine surgery scheduled as part of clinical care
18-80 years

Exclusion Criteria:

More than three doses of any opioid within one week of surgery
Pregnancy
Prisoners
Unable to provide consent
Emergency surgery
Chronic kidney disease stage 5 (GFR < 15 ml/min)
Severe hepatic impairment
Recent myocardial infarction (within the last 3 months)
Intervention: Hydromorphone
Trial phase: Not Applicable
ATC code: N02AA03 | N02AA53 | N02AG04
SMILES: [H][C@@]12CCC(=O)[C@]3([H])Oc4c(O)ccc5c4[C@]13CCN(C)[C@]2([H])C5
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 134
Group description: Patients will be randomized to receive a one time dose of 75 mcg intrathecal hydromorphone as part of their spinal anesthesia.

Hydromorphone: Hydromorphone is administered as part of spinal anesthesia for post-operative pain relief.
Eligibility criteria:
Inclusion Criteria:

American Society of Anesthesiologists (ASA) physical status II-III women presenting for elective cesarean delivery
Term gestation (37-42 weeks)
Desire to have a spinal anesthesia technique for cesarean delivery

Exclusion Criteria:

Any contraindication to the administration of a spinal technique for anesthesia
History of intolerance or adverse reaction to opioid medications
Chronic pain syndrome or current opioid use >30 oral morphine equivalents/day
Allergy or intolerance to acetaminophen, ketorolac, ibuprofen, or oxycodone
Current BMI > 50
Intervention: Morphine
Trial phase: Not Applicable
ATC code: A07DA52 | N02AA01 | N02AA51 | N02AG01
SMILES: [H][C@@]12C=C[C@H](O)[C@]3([H])Oc4c(O)ccc5c4[C@]13CCN(C)[C@]2([H])C5
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 134
Group description: Patients will be randomized to receive a one time dose of 150 mcg intrathecal morphine as part of their spinal anesthesia.

Morphine: Morphine is administered as part of spinal anesthesia for post-operative pain relief.
Eligibility criteria:
Inclusion Criteria:

American Society of Anesthesiologists (ASA) physical status II-III women presenting for elective cesarean delivery
Term gestation (37-42 weeks)
Desire to have a spinal anesthesia technique for cesarean delivery

Exclusion Criteria:

Any contraindication to the administration of a spinal technique for anesthesia
History of intolerance or adverse reaction to opioid medications
Chronic pain syndrome or current opioid use >30 oral morphine equivalents/day
Allergy or intolerance to acetaminophen, ketorolac, ibuprofen, or oxycodone
Current BMI > 50
Intervention: Propranolol
Trial phase: Phase 4
ATC code: C07AA05 | C07BA05 | C07FX01
SMILES: CC(C)NCC(O)COc1cccc2ccccc12
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 6
Group description: Propranolol 40 mg capsule, given once after fear activation procedure

propranolol: active treatment
Eligibility criteria:
Inclusion Criteria:

18-60 years of age at the time of consent
Principal Diagnosis of Social Anxiety Disorder, Performance only type
Has clinically significant fear of public speaking
Physically healthy
If female, non-pregnant and not nursing
Off all psychotropic drug for at least 4 weeks
A level of understanding sufficient to provide written informed consent to all required study tests and procedures.

Exclusion Criteria:

History of other serious psychiatric disorder
Current Major Depressive Disorder
Presence of developmental disorder or intellectual disability
SAD patients with SAD not of the performance only type
Women who are pregnant or nursing
Current use of psychiatric medication
Current substance use disorder
Persons planning to start another treatment during the study period.
Any significant medical condition that might increase the risk or participation (e.g., seizure disorder, respiratory disorders [e.g., bronchial asthma], cardiovascular disease [e.g., congestive heart failure, heart arrhythmias, sinus bradycardia and greater than first degree block ], low blood pressure [ < 90/60], diabetes, liver or kidney disorders)
Use of medications that might negatively interact with propranolol (e.g., ACE inhibitors; catecholamine depleting drugs, such as reserpine; calcium channel blockers; digitalis glycosides; haloperidol; chlorpromazine; aluminum hydroxide gel; phenytoin; phenobarbitone; rifampin; antipyrine; lidocaine; cimetidine; theophylline)
Intervention: ISOSORBIDE MONONITRATE
Trial phase: Phase 2
ATC code: C01DA14
SMILES: [H][C@]12OC[C@@H](O[N+](=O)[O-])[C@@]1([H])OC[C@@H]2O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 4
Group description: Monotherapy with isosorbide mononitrate
Eligibility criteria:
Inclusion Criteria:

Chronic kidney disease stage 3
Elevated left ventricular mass index or LV posterior wall thickness >1.4 cm documented in a clinically indicated echocardiographic or MRI examination within the previous 24 months or electrocardiographic LV hypertrophy
Stable medical therapy as defined by no addition, removal or change in dosage >100% of Angiotensin-converting-enzyme (ACE) inhibitors, angiotensin receptor blockers, beta-blockers, or calcium channel blockers for > 30 days
Current therapy with an ACE inhibitor, hydralazine or a statin, all of which have been shown to reduce nitrate tolerance

Exclusion Criteria:

A clinically- indicated stress test demonstrating significant myocardial ischemia within 1 year of enrollment, not followed by coronary revascularization
Rhythm other than sinus (i.e., atrial fibrillation)
Non-cardiac condition limiting life expectancy to <1 year
Current or anticipated future need for long acting organic nitrate therapy
Severe aortic or mitral valve disease
Hypertrophic cardiomyopathy
Known infiltrative or inflammatory myocardial disease (amyloid, sarcoid)
Pericardial disease
Primary pulmonary arteriopathy
History of myocardial infarction, unstable angina, percutaneous transluminal coronary angiography (PTCA) or coronary artery bypass grafting (CABG) within 60 days, or requirement for either PTCA or CABG at the time of consent
Resting heart rate (HR) >100 bpm
A reduced LV ejection fraction (EF<50%)
Known severe liver disease (AST >3x normal, alkaline phosphatase or bilirubin >2x normal)
Allergy to ISMN
Current therapy with phosphodiesterase inhibitors, such as sildenafil, vardanafil or tadalafil
Therapy with rosiglitazone
Current pregnancy or a positive urine pregnancy test; women who become pregnant during the study will be discontinued from the trial
Therapy with warfarin
History of kidney stones
History of glucose-6-phosphate dehydrogenase (G6PD) deficiency
Systolic blood pressure <110 mmHg or diastolic blood pressure <40 mmHg;
Contraindications to a cardiac MRI: (a) Central nervous system aneurysm clips; (b) Implanted neural stimulators; (c) Implanted cardiac pacemaker or defibrillator; (d) Cochlear implant; (e) Ocular foreign body (e.g. metal shavings); (f) Other implanted medical devices: (e.g. drug infusion ports); (g) Insulin pump; (h) Metal shrapnel or bullet; (i) Claustrophobia; (j) Extreme obesity rendering the patient unable to fit into narrow-bore scanners; (k) Unwillingness of the patient to undergo a cardiac MRI.
Intervention: Acetylcysteine
Trial phase: Phase 2
ATC code: R05CB01 | S01XA08 | V03AB23
SMILES: CC(=O)N[C@@H](CS)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 14
Group description: N-acetylcysteine capsules daily - up to 3200 mg

Medical Management Counseling: Brief alcohol counseling

N-acetylcysteine: Experimental supplement
Eligibility criteria:
Inclusion Criteria:

Male and female veterans
Ages 18-65 (inclusive)
A history of mTBI as defined by American Congress of Rehabilitation Medicine (ACRM), in the chronic, stable phase of recovery (>6 months from injury).
Current (past month [30 days]) Hazardous or Harmful Alcohol Use: Hazardous use is drinking that meets NIAAA criteria: Current (past 30 day) weekly drinking, consisting of an average of 15 standard drinks/week for men or 8 standard drinks/week for women. Harmful use is drinking behavior that meets DSM-5 criteria mild AUD.
Participants must express a desire to reduce or stop alcohol use.
Female subjects that must have a negative urine pregnancy test and must be either postmenopausal one year or practicing an effective birth control method.

Exclusion Criteria:

Unstable psychotic or bipolar disorders, dementia, or other psychiatric disorders judged to be unstable in the clinical judgment of the PI or study physician.
Clinically significant unstable medical conditions, in the clinical judgment of the PI or study physician.
Female patients who are pregnant or nursing.
Concurrent participation in another alcohol treatment study, or in any research study involving medications.
Requiring acute medical detoxification from alcohol based on a score of 12 or more on the Clinical Institute Withdrawal Assessment of Alcohol Scale (CIWA-AD).
NAC use in the past week prior to study entry.
Use of AUD treatment medications (disulfiram, naltrexone, or acamprosate) within the past week.
Participants who are legally mandated to participate in an alcohol treatment program.
Participants who have had a suicide attempt in the past 3 months or suicidal ideation, with intent, in the 30 days prior to enrollment.
Participants who in the opinion of the investigator should not be enrolled in the study because of the precautions, warnings or contraindications outlined in the NAC package insert.
Participants with known hypersensitivity to acetylcysteine
Intervention: Betamethasone
Trial phase: Phase 3
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 6
Group description: Dexamethasone 0.6mg/kg (maximum 15mg) PO x 1 dose

Dexamethasone: Dexamethasone 0.6mg/kg (maximum 15mg) PO x 1 dose
Eligibility criteria:
Inclusion Criteria:

Between the ages of 8 and 18 years (ie. > 8.0 years and < 18.0 years)
Diagnosed with migraine according to a modified version of International Classification of Headache Disorders 3rd edition (ICHD-3, beta version) where criterion A (ie. minimum of 5 prior episodes meeting criteria B-D) has been removed to increase sensitivity of diagnosis in the emergency department setting

Exclusion Criteria:

Received a dose of a steroid medication in the past 7 days
Known allergy to dexamethasone
Immunosuppressed
Cushing's syndrome
Known diabetes mellitus
Known peptic or duodenal ulcer or other major gastrointestinal illness (ex. ulcerative colitis)
Known myasthenia gravis
Glaucoma
Febrile at triage
History of head trauma in the past 7 days
Presence of any known active infection (eg. on antibiotics or antivirals, diagnosed with active infection in the ED, etc)
Current secondary headache (as per the treating physician's clinical impression)
Intervention: Omeprazole
Trial phase: Phase 4
ATC code: A02BC01 | A02BC05 | A02BD01 | A02BD05 | A02BD06 | A02BD16 | M01AE52
SMILES: COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 28
Group description: Genotype Guided PPI Dosing: PI type and dosing will be recommended in real time based on patients' CYP2C19 genotype / metabolizer phenotype.

No other ARM will be studied.

Genotype Guided PPI Dosing: Dosing of PPIs such as Prevacid and Nexium will be recommended based on CYP2C19 genotype information.
Eligibility criteria:
Inclusion Criteria:

Children diagnosed with Gastroesophageal Reflux Disease (GERD) or a stomach acid mediated condition for which a PPI is prescribed.
Currently taking or will be prescribed Proton Pump Inhibitor (PPI) medication
Parents/legal guardians and or child must also have access to the internet and a valid email address to complete weekly required forms.

Exclusion Criteria:

Children who have had peptic ulcer surgery;
with a history of PKU
with a history of previous adverse effects from PPI treatment or a sensitivity to aspartame (NutraSweet, Equal);
who are non-adherent including inability or unwillingness of the legal guardian to provide consent of unwillingness of the child to provide assent;
who are unable to take study medications;
who are unable to communicate via telephone or other device;
who do not have access to a computer with internet access
Intervention: Dapagliflozin
Trial phase: Phase 4
ATC code: A10BD15 | A10BD21 | A10BD25 | A10BK01
SMILES: CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 11
Group description: Dapagliflozin: 5mg pill taken once daily
Eligibility criteria:
Inclusion Criteria:

Type 2 diabetes with hypertension and on RAAS blocking drugs OR
Type 2 diabetes without hypertension and not on RAAS blocking drugs
Hemoglobin A1c between 7% and 9% (inclusive)
Estimated glomerular filtration rate (eGFR) ≥60 ml/min
Capacity to understand and sign informed consent

Exclusion Criteria:

Severe hepatic insufficiency and/or significant abnormal liver function defined as aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >3x upper limit of normal (ULN)
Total bilirubin >2.0 mg/dL
Positive serologic evidence of current infectious liver disease, including Hepatitis B viral antibody immunoglobulin M (IGM), Hepatitis B surface antigen, and Hepatitis C virus antibody
Estimated glomerular filtration rate (eGFR) <60 ml/min
Recent cardiovascular events with the last 2 months: acute coronary syndrome (ACS), hospitalization for unstable angina or acute myocardial infarction, acute stroke or transient ischemic attack (TIA), or post coronary artery revascularization
Congestive Heart Failure defined as New York Heart Association (NYHA) class IV, unstable or acute congestive heart failure
Pregnant or breastfeeding patients
Patients who, in the judgement of the investigator, may be at risk for dehydration
Blood pressure at enrollment: Systolic ≥165 mmHg and/or Diastolic ≥110 mmHg; At randomization: Systolic ≥160 mmHg and/or Diastolic ≥100 mmHg
Use of SGLT-2 inhibitor class drugs is an exclusion for all patients. For patients in the sulfonylurea arm, use of sulfonylurea class drugs is an exclusion.
Intervention: Indomethacin
Trial phase: Phase 4
ATC code: C01EB03 | M01AB01 | M01AB51 | M02AA23 | S01BC01 | S01CC02
SMILES: COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 1370
Group description: Subjects will be randomized to receive a 100-mg indomethacin suppository 30 min before ESWL.

indomethacin suppository: 100mg rectal indomethacin 30min before ESWL
Eligibility criteria:
Inclusion Criteria:

any patient with chronic pancreatitis and pancreatic stones (> 5 mm in diameter) undergoing P-ESWL
at least 18 years old
provides informed consent

Exclusion Criteria:

readmitted to the hospital during the enrollment of the study
contraindications to ESWL
suspected or established malignancy
pancreatic ascites
receiving NSAIDs within 7 days
contraindication to NSAIDs (including gastrointestinal hemorrhage within 4 weeks or renal dysfunction with serum creatinine >120 μmol/L)
presence of coagulopathy or received anticoagulation therapy within 3 days
acute pancreatitis within 3 days
known active cardiovascular or cerebrovascular disease
pregnant or breastfeeding women
without a rectum (ie, status post-total proctocolectomy)